Key points from article :
Researchers at Rice University are developing a new cancer implant that could revolutionise immunotherapy.
The implant, called HAMMR, would continuously monitor a patient's cancer and adjust their immunotherapy dose in real time.
The researchers believe that HAMMR could slash U.S. cancer deaths by more than 50%.
A first-phase clinical trial of HAMMR is slated to begin in the fourth year of the project.
The research is being funded by the Advanced Research Projects Agency for Health (ARPA-H).
The research is led by Dr. Omid Veiseh, an associate professor of bioengineering at Rice University.
